Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments
about
Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomicsSynergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruziDevelopment of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas DiseaseBenznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas DiseaseIdentification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade.Proteomic analysis of Trypanosoma cruzi response to ionizing radiation stressRavuconazole self-emulsifying delivery system: in vitro activity against Trypanosoma cruzi amastigotes and in vivo toxicity.Interferon-γ and other inflammatory mediators in cardiomyocyte signaling during Chagas disease cardiomyopathy.Chagas disease and the london declaration on neglected tropical diseases.Development of a community-based intervention for the control of Chagas disease based on peridomestic animal management: an eco-bio-social perspective.Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversityRapid and sensitive ultra-high-pressure liquid chromatography method for quantification of antichagasic benznidazole in plasma: application in a preclinical pharmacokinetic study.Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging.Curcumin Enhances the Anti-Trypanosoma cruzi Activity of Benznidazole-Based Chemotherapy in Acute Experimental Chagas Disease.Phenotypic Screening In Vitro of Novel Aromatic Amidines against Trypanosoma cruzi.Potential new clinical therapies for Chagas disease.Therapeutical approaches under investigation for treatment of Chagas disease.Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds.Targeting CYP51 for drug design by the contributions of molecular modeling.Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agentsIn vitro drug susceptibility of two strains of the wildlife trypanosome, Trypanosoma copemani: A comparison with Trypanosoma cruziAntitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.Therapeutic responses to different anti-Trypanosoma cruzi drugs in experimental infection by benznidazole-resistant parasite stock.Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benznidazole.Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment.Identification of di-substituted ureas that prevent growth of trypanosomes through inhibition of translation initiation.Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice.
P2860
Q28539047-7CF60674-1F0A-41DB-9964-8C44AE9EB059Q28540817-24009F71-4B9F-41C1-987F-BE93F8C8E9F1Q28548320-52483A25-78B2-4B96-90AE-2916658587BAQ28548342-580E8FD5-3373-4D18-922B-01C5891EAD57Q28551393-A45C8CFA-58D6-43B1-BD8D-310C4CC78D50Q33632160-3B1389C0-FD14-481D-8D17-457A866CFD3BQ33713176-7F1BEAE4-2073-4DAC-93EA-0C224DDCC506Q34179046-DC8857CF-C940-432E-98C5-1CE15DC316F1Q34315066-2DCE02C6-690D-49A5-BBD4-719AB09D82ECQ34986697-DB33FF79-8678-4F3B-B03A-555D4270CE9BQ35333873-0530A97F-AF62-4DC6-8FF8-617CE671A8ECQ35450419-B84969B8-CAD8-4024-B999-8C47584FC109Q35859935-AA665130-8477-4129-A84B-0F800F5F02E9Q36933422-9215506D-99DD-4918-801F-FF828C3F0886Q37120187-04EBCBBF-1C47-4C82-B805-6E2F3DB3C170Q38203330-69FF25EA-4103-4212-A0A2-853B8AB54647Q38214136-96B4457C-7790-4510-AF4A-D03B0B9F2F7BQ38256874-4BF72502-96DE-4CBE-B418-FC12AC3E8C94Q38777214-3CD024D4-F2B6-4A6C-894B-952687C50D42Q38917135-74C52EC0-CD5E-4B77-9FE6-21F8A84C5598Q38920814-44997743-F2AF-4383-A62D-14867B70AE70Q40389286-9201F602-59DC-4FFE-A6A0-8DC0425CE8B5Q41073713-D00A26ED-84F9-4EEA-A646-091E0D5AF027Q43807373-7282295F-1740-45CA-98DA-29AC2C11EAA5Q47115930-0E79894C-5F12-4627-8829-0F6C0FA0DCA1Q50142202-1D903718-A18F-4050-9CEC-6325BE8148E4Q51732698-D8865265-E54A-45F5-8352-18DF8CF434E5Q52648078-94C382C0-567D-4CE1-A7F9-B61C5EEF94D0
P2860
Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Benznidazole and posaconazole ...... tant and sequential treatments
@ast
Benznidazole and posaconazole ...... tant and sequential treatments
@en
Benznidazole and posaconazole ...... tant and sequential treatments
@nl
type
label
Benznidazole and posaconazole ...... tant and sequential treatments
@ast
Benznidazole and posaconazole ...... tant and sequential treatments
@en
Benznidazole and posaconazole ...... tant and sequential treatments
@nl
prefLabel
Benznidazole and posaconazole ...... tant and sequential treatments
@ast
Benznidazole and posaconazole ...... tant and sequential treatments
@en
Benznidazole and posaconazole ...... tant and sequential treatments
@nl
P2093
P2860
P3181
P1476
Benznidazole and posaconazole ...... tant and sequential treatments
@en
P2093
Ana Lia Mazzeti
Isabel Mayer de Andrade
Isabela Ribeiro
Ivo Santana Caldas
Julio A Urbina
Lívia de Figueiredo Diniz
Maria Terezinha Bahia
Tassiane Assíria F Martins
P2860
P3181
P356
10.1371/JOURNAL.PNTD.0002367
P407
P5008
P577
2013-08-15T00:00:00Z